Brightsurf Science News & Current Events

June 01, 2003
Donor cell injections in thymus improve outcomes for children getting heart transplants
Three to five years after heart transplantation, children who had received a bone marrow injection into their thymus during their transplants had significantly fewer

Pitt researchers develop guidelines for predicting low-risk patients with heart failure
New decision guidelines for identifying patients with low-risk heart failure may prevent unnecessary hospitalizations and could significantly reduce health care-related expenses, which according to the National Heart Lung and Blood Institute, cost the industry an estimated $21 billion per year.

Slight benefit seen in use of allogeneic stem cell transplantation for metastatic breast cancer
Examination of several multi-national cancer registries suggests that use of donor stem cells to treat metastatic breast cancer appears to delay progression of the disease in some patients.

Experimental cancer drug shrinks tumors, extends survival in metastatic colorectal cancer patients
An experimental cancer drug named bevacizumab (trade name Avastin) is the first

As we get older, memory accentuates the positive helping explain why aging can foster good feelings
Here's good news about aging: When it comes to remembering emotional images, we tend -- as we get older -- to do what the song said, and

Increased potential cure for people with aggressive blood cancer
Data presented today at the American Society of Clinical Oncology (ASCO) annual meeting showed that patients with an aggressive form of the blood cancer, non-Hodgkin's lymphoma (NHL), who were treated with MabThera plus standard chemotherapy (CHOP), have an improved chance of survival after three years compared with those treated with standard chemotherapy alone.

Chicago lake breeze effect could increase asthma risk
Chicago has long been known as one of the nation's worst cities for asthma sufferers.

Study uses test to predict breast cancer patients' response to chemotherapy
Researchers at the Breast Care Center at Baylor College of Medicine and The Methodist Hospital have developed a new test to predict which breast cancer tumors will respond to chemotherapy, potentially reducing unnecessary treatment for women with breast cancer, according to data presented at the American Society of Clinical Oncology annual meeting in Chicago.

Researchers discover possible diagnosis, treatment, vaccine for mad cow, prion diseases
Research led by scientists at the University of Toronto and Caprion Pharmaceuticals have uncovered the basis for a diagnostic, immunotherapy and vaccine, providing a way to detect and treat the brain-wasting damage of infectious prions like those found in mad cow disease and its human version, Creutzfeldt-Jakob Disease.

New radiotherapy strategy improves survival for lung cancer patients
According to findings presented at the annual meeting of the American Society of Clinical Oncology, a new therapeutic radiation strategy for non-small cell lung cancer leads to improved survival for patients with locally advanced disease.

Trial of drug to prevent tumors in child liver transplant patients discounts its utility
Following the first and largest clinical trial of its kind involving pediatric liver transplant patients, physicians say they have abandoned any notion of using the drug they thought might prevent Post-Transplant Lymphoproliferative Disease (PTLD), a complication more common in children whereby certain immune cells proliferate to form tumors, in favor of vigilant screening and a more conservative approach.

MRI may help find missed breast cancers in high risk women
New research presented today at the annual meeting of the American Society of Clinical Oncology finds that Magnetic Resonance Imaging (MRI)is a highly sensitive screening tool that may detect breast cancers missed by mammograms in women who are at increased risk for developing the disease.

New law eliminates a major barrier to cancer clinical trials
A California law enacted in January 2001 appears to have removed a major barrier to participation in clinical trials by cancer patients, according to research presented today at the annual meeting of the American Society of Clinical Oncology.

Early clinical trials show experimental drug shrinks tumors in patients with various cancers
An early clinical trial at the Cedars-Sinai Medical Center has shown that an experimental drug called 2C4 (trade name is Omnitarg) was effective to shrink tumors in patients with several different types of cancer.

New organ preservation solution easier to use
A new organ preservation solution offers comparable results to a solution currently in widespread use but it is more cost-effective and has several logistical advantages that makes it more practical for keeping donated livers viable before being transplanted, conclude University of Pittsburgh researchers who performed the first U.S. study to compare outcomes between HTK and the University of Wisconsin (UW) solution for the preservation of livers before transplantation.

Stanford researcher shows positive results of new chemotherapy combination for colon cancer
Researchers at Stanford University Medical Center have found that adding a new drug called Iressa to a combination of chemotherapy agents can significantly improve colon cancer treatment.

New treatment for advanced colorectal cancer offers relief from tumor-related symptoms
The addition of oxaliplatin to standard chemotherapy in patients with advanced colorectal cancer increases tumor response rate, lengthens time to tumor progression and offers a higher rate of relief from tumor-related symptoms, a new study finds.

Skin cancers typically found in older adults are being found in survivors of childhood cancer
Nonmelanoma skin cancers typically seen in older individuals are being detected in childhood cancer survivors at younger ages than the general population.

Childhood cancer survivors may experience heart problems sooner
Childhood cancer survivors may develop earlier and more extensive cardiovascular disease than doctors originally thought, according to two major clinical studies.

Yeast, wormwood & bacterial genes combine in microbial factory to make antimalarial drug
By combining 10 genes from three separate organisms into a single bacterial factory, UC Berkeley chemical engineers have developed a simpler, less expensive way to make an antimalaria

Targeted lung cancer treatment causes tumor regression in some patients
A new study suggests that a drug called erlotinib (TarcevaTM) has promising activity in patients with bronchioloalveolar cell carcinoma (BAC), a type of non- small cell lung cancer generally considered to be resistant to chemotherapy.

Doubling dose of Gleevec to treat GIST is not any more beneficial
Less is perhaps more when it comes to using Imatinib mesylate (GleevecTM) to treat advanced gastrointestinal stromal tumors (GIST), says a researcher from The University of Texas M.

Flu discovery to help thwart next pandemic
University of Melbourne scientists have found a chink in the flu virus's armour that could hold the key to preventing the next predicted pandemic.

Iressa may offer a maintenance advantage in lung cancer
An anti-cancer pill just approved by the Food and Drug Administration as the first in a novel class of agents may offer some maintenance benefits in advanced non-small cell lung cancer, say investigators who conducted a sub-analysis of several large international clinical trials.

Gleevec paired with chemotherapy to be further tested in advanced prostate cancer
Based on results of a Phase I trial that paired Imatinib mesylate (GleevecTM) with chemotherapy to treat advanced prostate cancer, a larger Phase II/III clinical trial has just been opened at The University of Texas M.

Gene screen predicts response to breast cancer chemotherapy
Researchers have taken a big step forward in the goal to

Weizmann institute scientists solve the 3-D structure of the enzyme involved in Gaucher disease
An interdisciplinary team of Weizmann Institute scientists has solved the three-dimensional structure of an enzyme called lucocerebrosidase.

Two-pronged attack against lung cancer using targeted therapies shows promise
Interim results of the first clinical trial to combine two experimental targeted therapies together to treat advanced non-small cell lung cancer found the regimen to be both safe and more beneficial than expected. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to